(-0.07%) 5 474.50 points
(-0.10%) 38 781 points
(-0.04%) 19 914 points
(0.21%) $80.50
(1.43%) $2.83
(0.22%) $2 334.10
(-0.19%) $29.34
(-0.23%) $968.70
(0.01%) $0.932
(-0.15%) $10.64
(0.07%) $0.788
(-1.87%) $86.79
Live Chart Being Loaded With Signals
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases...
Stats | |
---|---|
Šios dienos apimtis | 197 655 |
Vidutinė apimtis | 1.58M |
Rinkos kapitalizacija | 60.10M |
EPS | $-0.470 ( Q1 | 2024-05-09 ) |
Kita pelno data | ( $-0.420 ) 2024-08-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.770 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00400 (0.28%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-15 | Hunt Ronald | Buy | 16 500 | Option (Right to Buy) |
2024-05-15 | Boudreau Helen M | Buy | 16 500 | Option (Right to Buy) |
2024-05-15 | Liu Hui | Buy | 16 500 | Option (Right to Buy) |
2024-05-15 | Parmar Kush | Buy | 16 500 | Option (Right to Buy) |
2024-05-15 | Soteropoulos Paula | Buy | 16 500 | Option (Right to Buy) |
INSIDER POWER |
---|
91.89 |
Last 96 transactions |
Buy: 8 046 287 | Sell: 10 802 620 |
Tūris Koreliacija
Rallybio Corporation Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Rallybio Corporation Koreliacija - Valiuta/Žaliavos
Rallybio Corporation Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $-150 000 (0.00 %) |
EPS: | $-1.840 |
FY | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $-150 000 (0.00 %) |
EPS: | $-1.840 |
FY | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $-167 000 (0.00 %) |
EPS: | $-2.09 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-1.653 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Rallybio Corporation
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.